A Catalyst for Change: The European Cancer Patient's Bill of Rights
Mark Lawler(Queen's University Belfast), Patrick G. Johnston(Queen's University Belfast), Peter Johnson(Cancer Research UK), David Cameron(Corewell Health), Filippo de Braud(University of Milan), Richard Sullivan(Precision Spine (United States)), Denis Horgan, Kathy Oliver(Brain Tumour Charity), Josep Tabernero(Deaconess Hospital), R. Wilson, Nils Wilking(Sophiahemmet Hospital), PierFranco Conte(University of Padua), Sema Erdem(European CanCer Organisation), Sarper Diler(Myeloma UK), Martin J. Murphy(Virginia Commonwealth University), Bob Löwenberg(Unknown), Peter Kapitein, Michèle Barzach(Institut de Chirurgie Guidée par l'Image), Joan Kelly(Irish Cancer Society), Aimery de Gramont(Institut Hospitalier Franco Britannique), Mariano Barbacid(Spanish National Cancer Research Centre), Jan Geißler(Stiftung Patientensicherheit Schweiz), Gerlind Bode, Jonas Bergh(Karolinska Institutet), Liselotte Højgaard(University of Copenhagen), Francesco De Lorenzo(European CanCer Organisation), Sandra Kloezen(Dutch Cancer Society), Carlo La Vecchia(University of Milan), Harald zur Hausen(German Cancer Research Center), Ian Banks(European Disability Forum), Christoph Zielinski(Vienna General Hospital), Peter J. Selby(Centre for Addiction and Mental Health), John M. Fitzpatrick(Victoria Police), Volker Diehl(University of Cologne), Donal Hollywood(Trinity College Dublin), Jean‐Pierre Armand(Institut Gustave Roussy), Thierry Le Chevalier(Université Grenoble Alpes), Françoise Meunier(Fondation FondaMental), H. M. Pinedo(European Organisation for Research and Treatment of Cancer), Cornelis JH van de Velde(Leiden University), Jacek Jassem(Gdańsk Medical University)
Cited by 46
Related Papers
Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
|New England Journal of Medicine|2013|6.6k
Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel
|Blood|2016|5.9k
Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis
|The Lancet|2014|4.7k
The landscape of somatic copy-number alteration across human cancers
|Nature|2010|4.1k
Leucovorin and Fluorouracil With or Without Oxaliplatin as First-Line Treatment in Advanced Colorectal Cancer
|Journal of Clinical Oncology|2000|3.8k